CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. (Q46670683)
Jump to navigation
Jump to search
scientific article published in May 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. |
scientific article published in May 2008 |
Statements
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1 (English)
Ken-ichi Fujita
Wataru Yamamoto
Shoji Endo
Hisashi Endo
Fumio Nagashima
Wataru Ichikawa
Ryuhei Tanaka
Toshimichi Miya
Keiji Kodama
Yu Sunakawa
Masaru Narabayashi
Keisuke Miwa
Yuichi Ando
Yuko Akiyama
Kaori Kawara
Tetsuya Kamataki
Yasutsuna Sasaki
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference